Related Experiment Video
Updated: May 7, 2026
03:43
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
L Lorente Fernández1, E Monte Boquet1, F Pérez-Miralles2
1Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia, España.
Neurologia (Barcelona, Spain)
|September 17, 2013
Summary
The combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) effectively treated spasticity in 80% of multiple sclerosis patients. This cannabis-based treatment demonstrated an acceptable safety profile, offering a viable alternative for refractory symptoms.
Area of Science:
- Neurology
- Pharmacology
- Cannabinoid Science
Background:
- Spasticity is a prevalent and challenging symptom in multiple sclerosis (MS).
- Current treatments for MS spasticity may have limitations or side effects.
- Investigating novel therapeutic options is crucial for improving patient quality of life.
Purpose of the Study:
- To evaluate the clinical effectiveness of inhaled delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) for treating spasticity in MS patients.
- To assess the safety and tolerability of THC/CBD combination therapy in this population.
- To determine the real-world utility of THC/CBD in managing refractory MS spasticity.
Main Methods:
- Retrospective observational study design.
- Inclusion of patients treated with inhaled THC/CBD from April 2008 to March 2012.
- Evaluation of therapeutic response based on physician assessment and overall clinical impression.
Main Results:
- THC/CBD combination therapy was effective in 80% of the 50 evaluated MS patients.
- The median effective dose was 5 (2-10) inhalations/day.
- Common adverse events included dizziness, somnolence, and muscle weakness; treatment discontinuation occurred in 16 patients.
Conclusions:
- Inhaled THC/CBD demonstrates significant efficacy in managing refractory spasticity associated with multiple sclerosis.
- The combination therapy presents an acceptable safety and tolerability profile.
- THC/CBD represents a promising alternative to conventional treatments for MS-induced spasticity.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:29Spasmolytic Agents: Chemical Classification
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...